US 20210308275A1

(19) United States

(12) Patent Application Publication

Parker et al.

(10) Pub. No.: US 2021/0308275 A1

(43) Pub. Date: Oct. 7, 2021

(54) **LINKERS AND CONJUGATES**

(71) Applicants: **ASTRAZENECA AB**, Sodertalje (SE); **CAMBRIDGE ENTERPRISE LIMITED**, Cambridge, Cambridgeshire (GB)

(72) Inventors: **Jeremy Stephen Parker**, Macclesfield, Cheshire (GB); **Hannah Fiona Sore**, Cambridge, Cambridgeshire (GB); **David Robert Spring**, Cambridge, Cambridgeshire (GB); **Stephen James Walsh**, Cambridge, Cambridgeshire (GB)

(21) Appl. No.: **17/264,721**

(22) PCT Filed: **Jul. 31, 2018**

(86) PCT No.: **PCT/EP2018/070703**

§ 371 (c)(1),
(2) Date: **Jan. 29, 2021**

Publication Classification

(51) **Int. Cl.**

A61K 47/68	(2006.01)
A61K 47/54	(2006.01)
C07D 239/42	(2006.01)
A61K 31/704	(2006.01)
A61K 38/07	(2006.01)
A61P 35/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 47/6851*** (2017.08); ***A61K 47/545*** (2017.08); ***C07D 239/42*** (2013.01); ***A61K 47/6803*** (2017.08); ***A61K 38/07*** (2013.01); ***A61P 35/00*** (2018.01); ***A61K 31/704*** (2013.01)

(57) **ABSTRACT**

A conjugate comprising a protein or a peptide, a linker and an active agent, wherein the linker comprises the moiety of formula (III): (III) wherein two of A^1, A^2 and A^3 are N and the other of A^1, A^2 and A^3 is CH; X is selected from N, O and S, and Pep indicates where the moiety is linked to the protein or peptide, either directly or indirectly.

(III)